What is Ipamorelin

Ipamorelin è un pentapeptide sintetico derivato dal GHRP-1, appartenente allclasse dei growth hormone secretagogues (GHS). È in grado di legarsi in modo selettivo al recettore della grelina o growth hormone secretagogue receptor (GHS-R1a), stimolando il rilascio pulsatile dell’ormone della crescita (GH) senza alterare altri assi endocrini.
Studi preclinici e in vitro hanno dimostrato che Ipamorelin non modifica i livelli di ACTH, prolattina, FSH, LH, TSH o cortisolo, confermandone la selettività recettoriale e l’elevato profilo di sicurezza.
Rispetto a GHRP-6 e ad altri analoghi, presenta un’efficacia comparabile nel promuovere la secrezione di GH ma con minori effetti collaterali, diventando così un modello di riferimento per lo studio della specificità di legame recettoriale e dei meccanismi di crescita e riparazione dei tessuti muscoloscheletrici.

Ipamorelin and Corticosteroid-Related Effects

One of the most promising research areas for Ipamorelin involves its ability to counteract glucocorticoid-induced side effects. Glucocorticoids are widely used to treat inflammatory and autoimmune diseases, but their long-term administration can lead to muscle wasting, bone loss, and metabolic imbalance. Preclinical studies have shown that Ipamorelin can reduce or reverse the negative effects of glucocorticoids, improving anabolic balance and tissue repair. This protective role is thought to stem from its stimulation of GH and IGF-1 release, which help maintain muscle and bone integrity even under catabolic stress.

Ipamorelin and Bone Health

One of the most promising research areas for Ipamorelin involves its ability to counteract glucocorticoid-induced side effects. Glucocorticoids are widely used to treat inflammatory and autoimmune diseases, but their long-term administration can lead to muscle wasting, bone loss, and metabolic imbalance. Preclinical studies have shown that Ipamorelin can reduce or reverse the negative effects of glucocorticoids, improving anabolic balance and tissue repair. This protective role is thought to stem from its stimulation of GH and IGF-1 release, which help maintain muscle and bone integrity even under catabolic stress.

Ipamorelin and Muscle Growth

One of the most promising research areas for Ipamorelin involves its ability to counteract glucocorticoid-induced side effects. Glucocorticoids are widely used to treat inflammatory and autoimmune diseases, but their long-term administration can lead to muscle wasting, bone loss, and metabolic imbalance. Preclinical studies have shown that Ipamorelin can reduce or reverse the negative effects of glucocorticoids, improving anabolic balance and tissue repair. This protective role is thought to stem from its stimulation of GH and IGF-1 release, which help maintain muscle and bone integrity even under catabolic stress.

Ipamorelin and Glucose Metabolism

In diabetic animal studies, Ipamorelin has been shown to enhance insulin release, likely through indirect activation of calcium channels on pancreatic β-cells. This mechanism may improve glucose utilization and contribute to a better understanding of type 2 diabetes pathophysiology. Ongoing research continues to explore whether ghrelin receptor analogues like Ipamorelin could support pancreatic function or serve as preventive tools against metabolic disorders.

Research on Post-Operative Ileus (POI)

Post-operative ileus (POI) is a temporary paralysis of the gastrointestinal tract that frequently follows abdominal surgery, preventing normal food intake and slowing recovery. Several clinical proof-of-concept trials tested whether Ipamorelin could reduce POI duration. Results suggested that the peptide shortened time to first meal by approximately 12 hours and improved bowel motility. Although these early trials were eventually discontinued for commercial reasons, they provided valuable insight into Ipamorelin’s gastrointestinal activity and its potential in peri-operative recovery research.

Ipamorelin as a Ghrelin-Receptor Probe

Beyond its hormonal effects, Ipamorelin is a highly selective ghrelin receptor agonist. Overexpression of ghrelin receptors has been detected in several cancers and in heart failure. These discoveries have led researchers to investigate Ipamorelin as a positron emission tomography (PET) imaging probe. In vitro studies confirm that the peptide can be efficiently synthesized and radiolabeled for diagnostic imaging. Future in vivo work aims to establish standardized PET parameters for ghrelin-targeted molecular imaging.

Current Research Outlook

Despite its promising results, Ipamorelin was partly overlooked after the discontinuation of clinical studies on POI. However, it remains a peptide of great interest both as an experimental therapeutic agent and as a research tool for studying GH–ghrelin interactions and regenerative processes.
Its pharmacological profile — moderate side effects, low oral bioavailability but excellent subcutaneous bioavailability — makes it an ideal compound for use in preclinical models.
As with all Pepticore Aminos products, Ipamorelin is intended exclusively for research and laboratory use (Research Use Only), not for human or veterinary use.

Scientific References

1. PubMed — 9849822
2. PubMed — 11735244
3. PubMed — 10828840
4. PubMed — 15665799
5. PubMed — 27186127
6. ScienceDirect — S0223523418307347